Vertex Pharmaceuticals Incorporated (VRTX) key performance indicators and operating metrics (18 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP net income | 1.1B | FY2026-Q1 |
| Total revenue, outside the United States | 1.21B | FY2026-Q1 |
| Non-GAAP effective tax rate | 19.60 percent | FY2026-Q1 |
| GAAP effective tax rate | 17.70 percent | FY2026-Q1 |
| Income from operations | 1.14B | FY2026-Q1 |
| Combined GAAP research and development, acquired in-process research and development, and selling, general and administrative expenses | 1.5B | FY2026-Q1 |
| Non-GAAP net income per share - diluted | 5.03 USD_per_share | FY2025-Q4 |
| Non-GAAP operating income | 1.37B | FY2025-Q4 |
| Total CF product revenues | 3.19B | FY2025-Q4 |
| Non-GAAP operating margin | 43.00 percent | FY2025-Q4 |
| Total revenue, United States | 2.06B | FY2025-Q4 |
| TRIKAFTA/KAFTRIO | 2.57B | FY2025-Q4 |
| ALYFTREK | 380M | FY2025-Q4 |
| Other product revenues | 237M | FY2025-Q4 |
Back to VRTX overview · VRTX earnings · VRTX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.